Fluorescein sodium

Quick links

Choose a section

Quick links to important sections

Advertisements

Fluorescein sodium

Selected form

Advertisements
Advertisements

Method of action: Ophthalmologicals

Advertisements

Overview of Fluorescein sodium

Property Description
Active ingredient Fluorescein sodium (Fluorescein)
Forms Sterile ophthalmic solution, Sterile injectable solution
Pharmacological class Diagnostic Agents, Dyes, Ophthalmologicals
General purpose Contrast enhancement for diagnostic imaging
Origin Synthetic, Xanthene dye

What Type of Substance is Fluorescein Sodium?

Fluorescein sodium is primarily classified as a diagnostic agent and an organic xanthene dye used exclusively to aid medical examination, not to treat disease. This substance is a synthetic chemical entity and the highly water-soluble sodium salt of the fluorophore Fluorescein. Its function is non-therapeutic, serving only to enable observation and assessment. The substance's official classification places it firmly within the realm of Ophthalmologicals and Dyes utilized for assessment rather than therapeutic intervention. The medication is generally classified as a diagnostic staining agent used in ophthalmology, often in procedures involving the retina.


Composition and Available Forms

The substance is supplied as sterile, aqueous pharmaceutical solutions intended for either topical ophthalmic use or intravenous (IV) injection. As a salt, Fluorescein sodium is readily dispersed in a sterile, water-based vehicle, forming the basis for both its liquid preparations. The drug is formulated as a sterile solution for injection and topical use. This dual availability—as an eye drop applied to the surface or as a solution injected into a vein—is a key differentiating feature, allowing medical professionals to select the appropriate form based on the specific anatomical structure of the eye requiring visualization. This versatility is clinically recognized for facilitating detailed vascular assessment in diverse diagnostic settings.


General Purpose and Diagnostic Utility

The general purpose of Fluorescein sodium is to enable advanced contrast enhancement by functioning as a temporary fluorescent tracer visualization agent during specialized examinations, most notably fluorescein angiography. The molecule possesses the unique property of fluorescence, where it absorbs blue light and immediately re-emits a brilliant green light. This specific photochemical mechanism allows doctors to rapidly assess the integrity of the ocular surface and track the flow within the eye’s delicate blood vessels (diagnostic imaging), providing essential, objective data required for diagnosis. A typical scenario involves using the injectable form to identify microvascular leakage in the retina, a procedure that is widely supported by extensive clinical evidence.

Regulatory References

  1. NIH
  2. NIH
  3. fluorescein angiography
Advertisements

What side effects are possible with Fluorescein sodium?

Possible Side Effects and Safety Information

The information in this section summarizes the officially documented adverse reactions and safety statements for Fluorescein sodium, strictly based on government regulatory labeling (e.g., FDA, EMA).


Common and Expected Adverse Reactions

The most common and typically non-serious reactions, particularly after injection, are transient and expected. These include temporary discoloration of the skin (fading within 6–12 hours) and bright yellow discoloration of the urine (chromaturia, fading within 24–36 hours). Gastrointestinal effects such as nausea and vomiting commonly occur within the first few minutes after administration.

Serious Adverse Reactions

Official labeling documents rare but serious adverse events, primarily categorized as Immune System Disorders and Cardiac Disorders. These include severe, life-threatening hypersensitivity reactions such as anaphylaxis and anaphylactic shock, cardiac arrest, cardiovascular collapse, and seizures.

Additionally, leakage of the solution outside the vein (extravasation) can result in severe local tissue damage, including sloughing of the skin.

Safety Considerations for Special Populations

Population Regulatory Safety Note
Pregnancy Use is recommended only if clearly needed, as it is not known whether the dye can cause fetal harm.
Nursing Mothers The dye is excreted into human milk. Regulatory guidance suggests temporary cessation of breastfeeding (e.g., for 7 days) following treatment.

Restrictions and Limitations

The agent is contraindicated in individuals with a known hypersensitivity to fluorescein or any component of the formulation. Caution is advised for patients with a history of allergy or bronchial asthma, as intolerance reactions are more frequent in these groups.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents from agencies such as the FDA, EMA, and Health Canada indicate that no cases of systemic overdose with Fluorescein sodium injection have been reported, and minimal toxic effects are expected from an overdose. Therefore, specific signs and symptoms of systemic overdose are not defined in the official prescribing information.


Immediate Actions and Risks

While systemic overdose risk is considered minimal, the primary risk requiring immediate action is extravasation—the leakage of the solution from the blood vessel at the injection site. Because of the solution's high pH, extravasation can cause severe local tissue damage, including sloughing of the skin, subcutaneous granuloma, and toxic neuritis.


Regulatory Directives for Emergency Situations

  • Extravasation Management: If extravasation occurs, the injection must be discontinued immediately. Healthcare professionals are directed to implement conservative measures to treat the damaged tissue and relieve pain.
  • Suspected Overdose: For the management of any suspected systemic drug overdose, official government prescribing information directs healthcare professionals to contact a regional Poison Control Centre for guidance.

Patients should note that although overdose is rare, the prompt management of extravasation or any suspected severe reaction necessitates immediate professional medical attention.

Advertisements

Therapeutic Uses of Fluorescein sodium

What Fluorescein Sodium Aids in Diagnosis: Main Uses and Benefits

Fluorescein sodium is exclusively used as a diagnostic contrast agent that provides high-level visualization, meaning its benefit lies in providing the essential data for accurate diagnosis and supportive treatment planning. This dye is commonly used to help evaluate multiple ophthalmic conditions.

The agent is applied across domains where additional symptomatic support is needed to address issues manifesting as symptoms related to physical discomfort, such as acute eye pain, foreign body sensation, or blurred vision. It assists in the assessment of conditions characterized by periods of heightened symptoms, including corneal abrasions, ulcers, diabetic retinopathy, and age-related macular degeneration (AMD). The primary use involves highlighting injuries on the ocular surface or tracking leakage and blood flow in the posterior retina.

“The objective mapping provided by the dye supports patients by assisting the targeting of therapeutic interventions.”

This diagnostic benefit is commonly used in clinical settings that involve acute symptom patterns, such as assessing trauma, and in chronic monitoring scenarios to track disease progression. By enabling the reliable, high-contrast identification of issues, the agent contributes to reducing the overall risk of complications that may arise from surface injuries, and supports the management of vision in long-term vascular diseases.

Quick Fact: Support for Diagnostic Clarity
Support for Diagnostic Clarity: The dye assists patients by providing contrast enhancement to help clarify vague symptoms (like eye pain or floaters) into visual evidence, supporting timely, targeted intervention.

Regulatory References

  1. NIH StatPearls overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Fluorescein Sodium?

The eligibility for fluorescein sodium (used for angiography) is strictly defined by regulatory documents based on patient history and physiological state.

Contraindications and Restrictions

Category Regulatory Status & Requirement
Absolute Exclusion Contraindicated in patients with a known hypersensitivity or allergy to fluorescein sodium or any component of the product.
Conditional Use Caution is required for patients with a history of allergy or bronchial asthma, as they may have an increased risk of adverse reactions.

Special Populations

  • Pregnancy: Use is generally classified as Pregnancy Category C. It should be administered only if clearly needed and the potential benefit outweighs the potential risk.
  • Breastfeeding: Fluorescein sodium is excreted into human milk. Nursing mothers are required to temporarily discontinue breastfeeding for at least 4 to 7 days after administration, and discarded pumped milk during this period.
  • Pediatric Patients: While some regulatory bodies have established use in children, others advise that it should not be used in patients under 18 years of age because the safety and effectiveness in this group have not been established.

Usage is permitted for the general adult population where no contraindication or restriction applies, including geriatric patients, for whom no overall difference in safety has been observed compared to younger adults.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for fluorescein sodium identifies specific interactions related to systemic clearance, acute physiological response, and administration constraints.

Documented Interacting Substances

Interaction Type Interacting Medicines/Categories Constraint/Effect
Pharmacodynamic Beta-blocking agents (including eye drops) Potential to provoke severe anaphylactic reactions by interfering with the body's compensatory mechanisms and reducing adrenaline effectiveness.
Pharmacokinetic Organic Anion Transport Inhibitors (e.g., probenecid) May reduce the dye’s systemic clearance by competing for active renal excretion, potentially increasing systemic exposure.
Physical/Procedural Other intravenous solutions or drugs Must not be mixed or diluted in the same syringe or cannula due to risk of physical incompatibility.

Other Official Constraints

  • Timing Requirement: The intravenous cannula must be flushed with a sterile solution (e.g., sodium chloride 0.9%) both before and after the fluorescein injection.
  • Laboratory Interference: The dye and its metabolite can interfere with the analysis of blood and urinary parameters for up to 3 to 4 days after administration.
  • Population Note: Caution is required when using fluorescein in patients with pre-existing cardiovascular disease or diabetes mellitus who are receiving multiple concomitant drug therapies.
Advertisements

Mechanism of Action

The action of Fluorescein sodium is based solely on its photo-physical and tracing properties, not on conventional pharmacological targets like receptors or enzymes.

Mechanism of Photo-Physical Contrast

This xanthene dye's core mechanism is the immediate conversion of light energy. The molecule absorbs non-visible, high-energy blue light (approx 465-490 nm) and re-emits lower-energy yellow-green light (approx 520-530 nm), a phenomenon called fluorescence. This process provides the selective illumination needed to create sharp, visual contrast by differentiating the light output of targeted structures from surrounding tissue.


Tracing Vascular Integrity and Barrier Exclusion

Following systemic circulation, the dye acts as an inert tracer and is primarily excluded by the tight junctions of the Blood-Retinal Barrier (BRB) in healthy areas. It is reversibly bound to plasma proteins, primarily albumin. At pathological sites, the dye rapidly permeates the compromised barrier, visually demarcating areas of microvascular leakage. This mechanism establishes a visual demarcation of the functional status of vascular integrity.


️ Surface Adherence for Epithelial Mapping

When applied topically, the dye functions as an exclusion marker, unable to penetrate the intact, lipid-rich membranes of healthy epithelial cells. It selectively adheres only to the exposed, hydrophilic stroma where the outer protective layer has been lost. This mechanism provides the resulting physiological effect of surface integrity visualization, defining the spatial extent and morphology of the epithelial defects.

Advertisements

Dosage and Administration Information

Fluorescein sodium is used exclusively as a diagnostic agent, with administration patterns based on the ocular structure being examined.

Intravenous Administration

For diagnostic assessment of the retina and iris vasculature, fluorescein sodium is administered as a sterile intravenous injection. The standard adult dose is a single injection of 500 mg. A reduced dose of 200 mg is permissible when highly sensitive imaging systems are utilized.

Injection must be performed rapidly into the antecubital vein, typically at a rate of approximately 1 mL per second, to ensure timely systemic distribution. The injectable solution must not be mixed or diluted with other drugs. The IV cannula should be flushed with a 0.9% sterile sodium chloride solution both immediately before and after injection.

Topical Administration

For examination of the anterior segment of the eye, such as corneal integrity, fluorescein sodium is applied via the topical ophthalmic route. This typically involves using sterile strips impregnated with the dye. The strip must first be moistened with sterile water or saline solution before being touched gently to the conjunctiva or fornix, representing a single application per procedure.

Population-Specific Dosing

Dose adjustments are established for certain populations. The pediatric IV dose is calculated based on body weight at 7.7 mg/kg, up to a maximum total dose of 500 mg. For adult patients undergoing dialysis, the IV dose is reduced to 250 mg.

Advertisements

Recent Clinical Evidence

Fluorescein Sodium: Recent Clinical Evidence

Fluorescein sodium is primarily used as a diagnostic dye in ophthalmology for procedures such as angiography of the retina and iris vasculature. Recent research has focused on optimizing its use in established fields and exploring novel surgical applications.


Expanding Surgical and Diagnostic Uses

Clinical trials have investigated the application of fluorescein sodium beyond the eye, primarily in neurosurgery and vascular surgery. In neurosurgery, low-dose intravenous administration has been explored as an aid for intraoperative visualization during tumor resection, particularly for high-grade gliomas. The dye's tendency to accumulate where the blood-brain barrier is impaired can assist surgeons in differentiating malignant tissue from normal brain tissue, with studies suggesting its potential to enhance the extent of tumor removal.


Pharmacokinetics and Dosage Optimization

Pharmacokinetic studies confirm that following intravenous administration, fluorescein sodium rapidly distributes and is quickly cleared from the body, primarily through the kidneys. It is metabolized in the liver to fluorescein monoglucuronide. The clearance process typically results in the elimination of the dye and its metabolites within 48 to 72 hours, with temporary fluorescence in the urine lasting for up to 36 hours.

Research has explored the use of half-dose (250 mg) protocols for digital ultra-widefield fluorescein angiography, with findings suggesting that the reduced dose provides image quality comparable to the standard dose (500 mg) for most evaluations, except for the visualization of fine microvascular abnormalities. Studies have not identified overall differences in safety or effectiveness between elderly and non-elderly adult patients in established applications.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fluorescein sodium (FAQ)


Q: What are the signs of a rare allergic reaction to Fluorescein sodium?

According to official product information, rare allergic reactions (hypersensitivity) can occur after administration. Signs listed in regulatory documents include severe reactions like anaphylactic shock, difficulty breathing, widespread rash, hives, or swelling of the face or throat.


Q: Why did the doctor say my urine might look orange or bright yellow?

This is described in regulatory documents as a common physiological effect, as the dye and its metabolic breakdown products are removed from the body through the kidneys. Regulatory documents state that this process causes the urine to appear a bright yellow color, and this temporary change usually lasts for 24 to 36 hours after the injection.


Q: How long do the effects of the intravenous (IV) injection last in the body?

Official pharmacokinetic studies indicate the dye is rapidly cleared from the bloodstream by the kidneys. Approximately 80% of the administered dose leaves the body through the renal system within the first hour of injection, with complete systemic clearance noted within a day or two.


Q: Are there any age restrictions for who can receive Fluorescein sodium?

Official documents establish dosing guidelines for pediatric patients, indicating they can receive the dye under medical supervision. However, regulatory labels do not define a definitive lower age limit or specify particular restrictions for use in the elderly population.


Q: Can patients with kidney problems or liver problems use this dye?

The main route of excretion is through the kidneys. Regulatory documents specify that a dose reduction is specified for adult patients who are undergoing dialysis due to kidney impairment. Official documents do not typically provide specific guidance or dose adjustments for general hepatic (liver) impairment.


Q: Where can I find official safety data for the dye?

Detailed safety data, warnings, contraindications, and usage instructions are published by government drug agencies. This authoritative information is contained within the FDA DailyMed product insert (labeling) or the EMA Summary of Product Characteristics (SmPC).


Q: Is Fluorescein sodium considered a radiographic contrast agent?

Fluorescein sodium is officially categorized as a diagnostic contrast medium that relies on its ability to fluoresce, or re-emit light, when activated by a specific blue light source. This is a photo-physical mechanism, which differs from how radiographic (X-ray) contrast agents work.


Q: Is temporary yellowing of the skin a normal side effect of the injection?

Temporary skin discoloration is listed as a very common adverse reaction following an intravenous injection. This yellowing occurs as the dye enters the bloodstream and regulatory documents indicate that the effect typically fades within 6 to 12 hours.


Q: How long does the temporary color change from the dye usually last?

Official information notes that the skin discoloration typically fades within 6 to 12 hours of the injection. However, the resulting color change in the urine persists longer, generally lasting for 24 to 36 hours.


Q: Can Fluorescein sodium cause me to see halos or temporary blurry vision?

Official regulatory documents list a few transient visual changes as common adverse reactions following the use of the dye. These reactions can include temporary blurring of vision or general eye irritation.


Q: Does the eye drop sting or feel uncomfortable when it’s administered?

Local adverse reactions are noted in regulatory information for the topical application. These include a stinging or burning sensation in the eye, as well as an increase in tear production.


Q: Can I wear my contact lenses right after the test is performed?

Official warnings address the removal of soft contact lenses before the topical application of the dye, as the dye can stain the soft lens material. For soft lenses, reinsertion is constrained to waiting for one hour after the procedure.


Q: How quickly does Fluorescein sodium start to work after application?

The effect is nearly instant due to the dye’s photo-physical properties. Following an intravenous injection, fluorescence in the vessels is typically visible within seconds. After topical application, the visualization of the eye surface is noted to be immediate upon the use of the proper light source.


Q: How long does the staining on the eye surface last?

When applied topically, the dye adheres only to areas of the eye surface that have a defect. The dye is not intended to remain long-term, and is typically washed away quickly by the eye’s natural tear production and blinking action.


Q: Is Fluorescein sodium safe to use during pregnancy?

Official regulatory labels state that the drug is not recommended for use during pregnancy. Use during pregnancy is constrained to situations where the potential diagnostic benefit is determined to outweigh the risks to the fetus.


Q: Is it normal for my vision to be sensitive to light right after the test?

Official regulatory documents list photophobia (an increased sensitivity to light) as a common adverse reaction after the dye is administered. This effect is usually temporary.


Q: Does Fluorescein sodium contain any preservatives that might cause irritation?

Official inactive ingredient lists indicate that some formulations of the solution or topical strips do contain preservatives. These can include agents such as Chlorobutanol or Benzalkonium Chloride.


Q: Why do some people experience a metallic taste after the IV injection?

Experiencing a different taste is a very common adverse reaction listed in regulatory documents following the intravenous injection. This change in taste sensation, known as dysgeusia, is often reported as a temporary metallic taste.


Q: How long do I need to wait after the test before driving?

Official product information advises that the ability to drive or operate machinery may be affected due to the risk of temporary visual disturbances. This precaution is necessary because the dye may cause temporary blurring of vision.


Q: Is Fluorescein sodium a prescription-only substance?

According to general regulatory classifications, Fluorescein sodium is designated as a prescription-only medicine. Its use is limited to or under the direction of qualified medical professionals.


Q: What should I know about using this dye if I am breastfeeding?

Official warnings state that the interruption of breastfeeding is recommended for at least four days after the dye has been administered. Milk collected during this period is specified for disposal.

Advertisements

How should Fluorescein sodium be stored and disposed of?

How to Store and Dispose of Fluorescein Sodium

Fluorescein sodium is stored according to regulatory requirements to maintain its stability and quality. The injectable solution must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the product from freezing and to keep it in its original container.

Storage and Handling Requirements

Requirement Description
Temperature Controlled room temperature (20°C to 25°C).
Protection Must be protected from freezing and, for some presentations, from light.
Stability Check Visually inspect for particulate matter or discoloration before use.
Child Safety Keep out of the sight and reach of children.

Disposal

Disposal of any unused product or waste material must be conducted according to local requirements and established procedures for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluorescein sodium found in:

A-Z Index: